(S (NP (NNP Deep) (NN generative) (NNS models)) (VP (VBP are) (VP (VBG attracting) (NP (JJ great) (NN attention)) (PP (IN as) (NP (NP (DT a) (JJ new) (NN promising) (NN approach)) (PP (IN for) (NP (JJ molecular) (NN design))))))) (. .))
(S (NP (NP (DT All) (NNS models)) (VP (VBN reported) (ADVP (RB so) (RB far)))) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (DT either) (NP (NP (JJ variational) (NN autoencoder)) (PRN (-LRB- -LRB-) (NP (NNP VAE)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ generative) (JJ adversarial) (NN network)) (PRN (-LRB- -LRB-) (NP (NNP GAN)) (-RRB- -RRB-))))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ new) (NN type) (NN model)) (VP (VBN based) (PP (IN on) (NP (NP (DT an) (ADJP (RB adversarially) (VBN regularized)) (NN autoencoder)) (PRN (-LRB- -LRB-) (NP (NNP ARAE)) (-RRB- -RRB-))))))) (. .))
(S (S (NP (PRP It)) (ADVP (RB basically)) (VP (VBZ uses) (NP (NP (JJ latent) (NNS variables)) (PP (IN like) (NP (NNP VAE)))))) (, ,) (CC but) (S (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (DT the) (NN latent) (NNS variables)))) (VP (VBZ is) (VP (VBN obtained) (PP (IN by) (NP (NP (JJ adversarial) (NN training)) (PP (IN like) (PP (IN in) (NP (NNP GAN))))))))) (. .))
(S (NP (DT The) (NN latter)) (VP (VBZ is) (VP (VBN intended) (S (VP (TO to) (VP (VB avoid) (NP (DT both) (NP (NP (JJ inappropriate) (NN approximation)) (PP (IN of) (NP (JJ posterior) (NN distribution))) (PP (IN in) (NP (NNP VAE)))) (CC and) (NP (NP (NN difficulty)) (PP (IN in) (S (VP (VBG handling) (NP (JJ discrete) (NNS variables))))) (PP (IN in) (NP (NNP GAN)))))))))) (. .))
(S (NP (PRP$ Our) (NN benchmark) (NN study)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP ARAE)) (ADVP (RB indeed)) (VP (VBD outperformed) (NP (JJ conventional) (NNS models)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN validity) (, ,) (JJ uniqueness) (, ,) (CC and) (NN novelty)) (PP (IN per) (NP (VBN generated) (NN molecule))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (NP (NP (JJ successful) (JJ conditional) (NN generation)) (PP (IN of) (NP (JJ drug-like) (NNS molecules))) (PP (IN with) (NP (NNP ARAE)))) (PP (IN for) (NP (NP (DT both) (NNS cases)) (PP (IN of) (NP (ADJP (JJ single) (CC and) (JJ multiple)) (NNS properties) (NN control)))))) (. .))
(S (PP (IN As) (NP (DT a) (JJ potential) (NN real-world) (NN application))) (, ,) (NP (PRP we)) (VP (MD could) (VP (VB generate) (NP (NP (NNP EGFR) (NNS inhibitors)) (VP (VBG sharing) (NP (NP (DT the) (NNS scaffolds)) (PP (IN of) (NP (VBN known) (JJ active) (NNS molecules)))) (SBAR (IN while) (S (VP (VBG satisfying) (NP (JJ drug-like) (NNS conditions)) (ADVP (RB simultaneously))))))))) (. .))
